Please login to the form below

Not currently logged in
Email:
Password:

Acorda Therapeutics

This page shows the latest Acorda Therapeutics news and features for those working in and with pharma, biotech and healthcare.

CHMP backs Bayer’s tumour-agnostic drug Vitrakvi

CHMP backs Bayer’s tumour-agnostic drug Vitrakvi

There were two other positive opinions on new medicines at the CHMP meeting last week, with the panel backing Acorda Therapeutics’ inhaled Inbrija (levodopa) for the treatment of symptoms of ‘off’ ... look at two other recent rejections –

Latest news

  • Biotech leaders jump into US free speech debate Biotech leaders jump into US free speech debate

    Alnylam chief executive John Maraganore, Decibel Therapeutics’ CEO Steve Holtzman, Acorda CEO Ron Cohen and Jeremy Levin of Ovid Therapeutics are the main signatories to the letter published In Nature, but

  • Biogen pays $590m for Pfizer cognition drug Biogen pays $590m for Pfizer cognition drug

    The biotech company has also been linked to a possible takeover offer for Acorda Therapeutics and its Parkinson’s diseases candidates Inbrija (inhaled levodopa) and SYN-201.

  • Acorda acquires Biotie to expand in Parkinson's disease Acorda acquires Biotie to expand in Parkinson's disease

    Strikes $363m deal for Finnish firm. Acorda Therapeutics has agreed to buy Finland's Biotie Therapies in a $363m deal that swells its pipeline of Parkinson's disease (PD) drug candidates. ... The deal will also give Acorda four phase III programmes that -

  • A competitive edge

    TBR 652 is currently being developed by Tobira Therapeutics. A phase IIa proof-of-concept trial evaluated the antiviral activity, safety and pharmacokinetics of TBR 652 in treatment-experienced, CCR5-naïve ... Philippines. Dalfampridine . Ampyra

  • MS symptom drug approved in US

    The drug will be manufactured by Irish pharmaceutical company, Elan, and will be distributed in the US by Acorda Therapeutics. ... Shane Cooke, executive vice president and head of Elan Drug Technologies said: "We wish to congratulate Acorda Therapeutics

More from news
Approximately 1 fully matching, plus 5 partially matching documents found.

Latest Intelligence

  • Deal Watch table for October 2014 Deal Watch table for October 2014

    847. Lineage Therapeutics/Impax Laboratories. Company acquisition. Includes generic and branded products such albendazole and epinephrine. ... 675. Acorda Therapeutics/Civitas Therapeutics. Company acquisition. Includes CVT 301 in P3 for Parkinson's as

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Latest appointments

  • Dr Catherine Strader joins Acorda Therapeutics’ board Dr Catherine Strader joins Acorda Therapeutics’ board

    Acorda Therapeutics has expanded its board of directors with the addition of Dr Catherine Strader. ... Dr Ron Cohen, Acorda's president and chief executive officer, said: “Catherine brings decades of experience as both a drug developer and

  • Acorda Therapeutics appoints chief medical officer Acorda Therapeutics appoints chief medical officer

    New York-based biotech Acorda Therapeutics has appointed Dr Burkhard Blank as its chief medical officer. ... Burkhard brings to Acorda an impressive record of successful drug development and approved NDAs.

More from appointments
Approximately 2 fully matching, plus 0 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Videum Health

Videum Health is a premium video platform that offers brands innovative engagement strategies to reach targeted healthcare audiences on a...

Latest intelligence

Theodora Harold
A snapshot of Crescendo Biologics
PME talks to CEO Theodora Harold...
eyeforpharma Marketing and Customer Innovation Europe
By Richard Springham...
US Drug pricing
The Golden Goose
Why it’s so hard for the US to curb runaway drug prices...

Infographics